Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients using a ...
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by ...